OSTX
Price
$1.27
Change
-$0.00 (-0.00%)
Updated
Oct 22, 04:59 PM (EDT)
Capitalization
59.44M
22 days until earnings call
Intraday BUY SELL Signals
SLS
Price
$11.35
Change
-$0.79 (-6.51%)
Updated
Oct 22 closing price
Capitalization
2.29B
20 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

OSTX vs SLS

OSTX vs SLS Comparison Chart in %
View a ticker or compare two or three
VS
OSTX vs. SLS commentary
Oct 23, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OSTX is a Hold and SLS is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for OSTX with price predictions
Oct 22, 2026

OSTX sees MACD Histogram just turned negative

OSTX saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 21, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 18 instances where the indicator turned negative. In 16 of the 18 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OSTX as a result. In 37 of 42 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

OSTX moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OSTX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 7 of 8 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OSTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for OSTX entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +8.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where OSTX advanced for three days, in 91 of 106 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

OSTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-4.989) is normal, around the industry mean (2.973). P/E Ratio (-1.165) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 24 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. OSTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OSTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SLS with price predictions
Oct 22, 2026

SLS in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 16, 2026

SLS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 36 cases where SLS's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 89%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SLS as a result. In 72 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.

The Moving Average Convergence Divergence (MACD) for SLS just turned positive on October 21, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 34 of 39 cases over the following month. The odds of a continued upward trend are 87%.

Following a +15.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 244 of 280 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The 10-day moving average for SLS crossed bearishly below the 50-day moving average on September 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.

The Aroon Indicator for SLS entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.651) is normal, around the industry mean (2.973). SLS has a moderately low P/E Ratio (-51.591) as compared to the industry average of (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 89 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

FUNDAMENTALS RATINGS
SLS: Fundamental Ratings
SLS
OUTLOOK RATING
1..100
15
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
PROFIT vs RISK RATING
1..100
89
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
34
P/E GROWTH RATING
1..100
30
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
OSTXSLS
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 1 day ago
85%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 15 days ago
86%
Bullish Trend 2 days ago
87%
Declines
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 7 days ago
84%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
85%
COMPARISON
Comparison
Oct 23, 2026
Stock price -- (OSTX: $1.27 vs. SLS: $11.35)
Brand notoriety: OSTX and SLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OSTX: 47% vs. SLS: 93%
Market capitalization -- OSTX: $59.44M vs. SLS: $2.29B
OSTX [@Biotechnology] is valued at $59.44M. SLS’s [@Biotechnology] market capitalization is $2.29B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $135.64B. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OSTX’s FA Score shows that 2 FA rating(s) are green while SLS’s FA Score has 2 green FA rating(s).

  • OSTX’s FA Score: 2 green, 3 red.
  • SLS’s FA Score: 2 green, 3 red.
According to our system of comparison, SLS is a better buy in the long-term than OSTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OSTX’s TA Score shows that 4 TA indicator(s) are bullish while SLS’s TA Score has 4 bullish TA indicator(s).

  • OSTX’s TA Score: 4 bullish, 6 bearish.
  • SLS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, SLS is a better buy in the short-term than OSTX.

Price Growth

OSTX (@Biotechnology) experienced а -8.63% price change this week, while SLS (@Biotechnology) price change was +0.09% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.

Reported Earning Dates

OSTX is expected to report earnings on Nov 13, 2026.

SLS is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (-1.10% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
OSTX
Daily Signal:
Gain/Loss:
SLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

OSTX and

Correlation & Price change

A.I.dvisor tells us that OSTX and ABCL have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OSTX and ABCL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OSTX
1D Price
Change %
OSTX100%
-1.57%
ABCL - OSTX
31%
Poorly correlated
-7.11%
UNCY - OSTX
31%
Poorly correlated
+1.81%
CRDF - OSTX
31%
Poorly correlated
-1.17%
ONCY - OSTX
31%
Poorly correlated
-2.19%
SLS - OSTX
30%
Poorly correlated
-6.51%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SAPH45.161.57
+3.61%
SAP SE ADRHEDGED
BNDS47.07-0.10
-0.22%
Infrastructure Capital Bond Income ETF
RNRG31.39-0.29
-0.92%
Global X Renewable Energy Producers ETF (RNRG)
ECON32.38-1.03
-3.07%
Columbia Research Enhanced Emerging Economies ETF (ECON)
MGNR46.92-1.49
-3.08%
American Beacon GLG Natural Resources ETF (MGNR)